RxDoctor Payments Data

Herby Hay, MD

Family Medicine · Louisville, KYNPI 1811079411

Payments from drug & device makers

$5,529in general payments, 2019–2025

Across 368 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$814
  • Pfizer$548
  • Amgen$362
  • GSK$303
  • Astellas Pharma US Inc$278
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$5,44198%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,529 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$243,649
Medicare patients
591
Services billed
2,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$248,228
OzempicSemaglutide85$89,081
MounjaroTirzepatide67$78,143
JardianceEmpagliflozin73$69,267
JanuviaSitagliptin Phosphate59$62,645
FarxigaDapagliflozin Propanediol68$56,704
XareltoRivaroxaban39$48,858
LinzessLinaclotide31$36,475
RybelsusSemaglutide22$28,491
MyrbetriqMirabegron34$22,314
JanumetSitagliptin Phos/Metformin Hcl30$18,782
Janumet XrSitagliptin Phos/Metformin Hcl15$18,094
Bydureon BciseExenatide Microspheres17$13,150
GemtesaVibegron13$13,077
LexaproEscitalopram Oxalate16$12,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$548$248,228251 claims
Novo NordiskOzempic, Rybelsus$814$117,572107 claims
MerckJanuvia, Janumet, Janumet Xr$63$99,521104 claims
Lilly USA, LLCMounjaro$257$78,14367 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$152$76,208102 claims
Boehringer IngelheimJardiance$133$69,26773 claims
AbbVieLinzess, Lexapro, Synthroid$1,090$54,520139 claims
Johnson & JohnsonXarelto$106$48,85839 claims
Astellas Pharma US IncMyrbetriq$278$22,31434 claims
Sumitomo Pharma America, Inc.Gemtesa$116$13,07713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$6,596580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →